PharmaMar
↗Colmenar Viejo, Spain
PharmaMar is a leading Spanish biopharmaceutical company founded in 1986, specializing in the discovery, development, and commercialization of innovative oncology treatments derived from marine sources. The company maintains the world's largest collection of marine invertebrates and utilizes a unique research platform to isolate and synthesize antitumor compounds.
Beyond its core oncology business, PharmaMar operates in the RNAi therapeutics space through its subsidiary, Sylentis, and maintains a legacy consumer chemicals division. The company is recognized for its high commitment to R&D, consistently ranking among the top investors in research relative to revenue within the European pharmaceutical sector.
CLASSIFICATION
SIZE & FINANCIALS
Employees:501-1000
Revenue:$221.4M (2025)
Founded:1986
Ownership:public
Status:operating
STOCK
Exchange:BME (Bolsas y Mercados Españoles)
Ticker:PHM
Market Cap:$1.81B
PIPELINE
Stage:Commercial
Lead Drug Stage:Commercial
Modalities:Small molecule, RNAi
Trial Phases:Phase 3: 2
FDA Approvals:1
EMA Approvals:3
CORPORATE STRUCTURE
Subsidiaries:Sylentis, GENOMICA
Key Partnerships:Janssen Products, LP (Yondelis licensing), Globant (AI collaboration)
COMPETITION
Position:Niche Player
LEADERSHIP
Key Executives:
Javier Jimenez - Chief Medical Officer
LINKS
Website:pharmamar.com
⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of PharmaMar and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with PharmaMar. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.